Search company, investor...

Groove Biopharma


Series B | Dead

Total Raised


Last Raised


About Groove Biopharma

Groove Biopharma, fka Mirina Corporation, develops therapeutics using Minor Groove Binder Technology (MGB) to affect cellular processes involving microRNAs. Groove holds a license to the technology from Elitech for use in therapeutics. Elitech developed and patented novel methods for preparing oligonucleotides appended with chemical agents, that modify binding to target sequences in RNA or DNA. By incorporating this technology into miRNA therapeutics, Groove Biopharma's novel MGB-oligonucleotide compounds are anticipated to exhibit superior properties, such as enhanced target selectivity, better potency, and improved pharmacological activity. Groove Biopharma's technology presents promising potential for treating a wide range of diseases including cancers, infectious disease and metabolic disorders.

Headquarters Location

1616 Eastlake Ave. E. Suite 202

Seattle, Washington, 98102,

United States

Missing: Groove Biopharma's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Groove Biopharma's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Groove Biopharma

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Groove Biopharma is included in 2 Expert Collections, including Cancer.



4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.


Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

Latest Groove Biopharma News

Accelerator Gets New Chief Scientist, David McElligott

Mar 29, 2012

XconomySeattle —  The Accelerator, the place that starts more biotech companies than any other outfit in Seattle, has had a changing of the scientific guard. David McElligott, the chief scientific officer at one of Accelerator’s portfolio companies, Groove Biopharma, has been promoted to the role of chief scientific officer at Accelerator. He replaces Pat Gray, who announced this week he’s moved to take a new job as a scientific fellow at Seattle-based Omeros (NASDAQ: OMER ). McElligott earned his stripes at Accelerator the past several years at Groove, which recently raised $6 million after hitting a series of milestones with its microRNA drug development programs. He’s a former senior director of biological sciences at Bothell, WA-based Icos, where he got to know Gray and several other scientists who have migrated over the years to Accelerator. The new job means that McElligott will have a broader role in day-to-day R&D decisions across the Accelerator portfolio, which currently includes three active companies— Oncofactor , Acylin Therapeutics , and Groove . He’ll also be involved in scouting new investments. David McElligott, Accelerator's chief scientific officer “David has consistently impressed the team and our investors with his professional, steady and thoughtful approach, his broad scientific and drug development expertise, his agility and his innovative instincts,” said Accelerator CEO Carl Weissman , in a statement. Gray added: “I have worked with David McElligott for 9 years both at Icos and Accelerator and could not think of a better person to whom to hand off the scientific reins.” Accelerator was founded in 2003 by the Institute for Systems Biology, Alexandria Real Estate Equities, and a network of venture investors that sought to bring scientific expertise, facilities, and capital together to help create more biotech companies with big potential. It has formed 12 startups since inception, four of which have spun out in one form or another as their own as independent venture-backed companies—Allozyne, Theraclone Sciences, VLST, and Integrated Diagnostics. The Accelerator is currently backed by Amgen Ventures, Arch Venture Partners, OVP Venture Partners, PPD, Alexandria Real Estate Equities, WRF Capital, and the Institute for Systems Biology. McElligott will be one of the featured speakers at the big Xconomy Seattle event next week, “ Reinventing Biotech’s Business Model .” He will be on hand along with Weissman to talk about how to keep the science progressing at Groove in an environment with limited venture capital.

Groove Biopharma Frequently Asked Questions (FAQ)

  • Where is Groove Biopharma's headquarters?

    Groove Biopharma's headquarters is located at 1616 Eastlake Ave. E., Seattle.

  • What is Groove Biopharma's latest funding round?

    Groove Biopharma's latest funding round is Series B.

  • How much did Groove Biopharma raise?

    Groove Biopharma raised a total of $10.39M.

  • Who are the investors of Groove Biopharma?

    Investors of Groove Biopharma include ARCH Venture Partners, WRF Capital, OVP Venture Partners, Alexandria Venture Investments, Versant Ventures and 5 more.

  • Who are Groove Biopharma's competitors?

    Competitors of Groove Biopharma include Lipella Pharmaceuticals, Longevica, NGM Biopharmaceuticals, Rotation Medical, ZEDIRA and 15 more.

Compare Groove Biopharma to Competitors

Bolder BioTechnology

Bolder BioTechnology, Inc. uses advanced protein engineering technologies to create human protein pharmaceuticals with enhanced therapeutic properties. Most protein pharmaceuticals are rapidly eliminated by the body, which limits their effectiveness and requires that they be administered by frequent, often daily, injection. The company's products are designed to last longer in the body, which aims to allow them to be administered less frequently, e.g., once per week to once per month, and maximizes their therapeutic benefits to patients. Company scientists combine protein structure/function information with targeted protein modification technologies to rationally design long-acting protein pharmaceuticals that, in many cases, are 10-100-fold more potent than competing products prepared using non-targeted protein modification technologies. Bolder BioTechnology has a robust pipeline of products in preclinical development, including products for the treatment of hematological and endocrine disorders, cancer and infectious disease. The company intend to commercialize these products independently and through strategic alliances with corporate partners.

Cellerant Therapeutics Logo
Cellerant Therapeutics

Cellerant Therapeutics is a clinical stage biotechnology company focused on the regulation of the hematopoietic (blood-forming) system. The Company is developing human stem cell and antibody therapies for oncology applications and blood-related disorders. Cellerant's lead product, CLT-008 is currently in two Phase 1 clinical trials in patients with hematological malignancies. The Company also has a Cancer Stem Cell (CSC) antibody discovery program focused on therapies for acute myeloid leukemia, multiple myeloma and myelodysplastic syndrome.

Punjab Biotechnology Incubator Logo
Punjab Biotechnology Incubator

Punjab Biotechnology Incubator (PBTI) welcomes users to its state-of-the- art Agri & Food Testing Laboratory set up at SAS Nagar (Mohali), the hub of Biotechnology and Information Technology in Punjab. PBTI is a State Govt. Undertaking registered as a "˜Society for Biotechnology Incubator' under the Society Registration Act 1961 and is professionally governed by Governing Council of the Society under the chairmanship of Chief Secretary, Govt. of Punjab. The day to day affairs are managed by Chief Executive Officer, supported by technical professionals of high caliber.

Chroma Therapeutics

Chroma Therapeutics is a biotechnology company founded to exploit the potential of chromatin biology for cancer drug discovery. Chroma is focused on the identification of anti-cancer agents that combine the efficacy of cytotoxics with the tumour cell selectivity of modern targeted therapeutics. Based in Oxford, UK, Chroma is developing a pipeline of anti-cancer drugs.


Adriacell s.r.l is a biotech company focused in oncology pharmaceuticals founded in Basovizza (Trieste) in March 2004 by Prof. Christian Kuehne, an Austrian citizen.nThe company is leveraging its efforts and scientific expertise to successfully solve important worldwide health problems; in particular, it has been striving to develop a new class of anti-tumour therapeutics and to create a series of powerful diagnostics for the early detection of cancer progression. The company is also developing new and highly powerful delivery solutions through small molecules as the basis for a new class of anti-infective drugs.nAdriaCell owns a patented system that can be used for the study of events subsequent to DNA double strand breaks, a very important issue for cancer research and diagnostics. Adriacell is currently evaluating a new class of therapeutics for cancer; its main lead compound is about to enter the pharmacokinetic and toxicology phases.nAdriacell Vision is to become a leader biotech drug development company concentrated in the development of solutions (treatment and diagnostics) for tumours characterized by low probability of survival for patients and of anti infective agents. Thanks to future developments in research and test activities Adriacell solutions will hopefully become useful in a wider range of pathologies.

Receptor Logic

Receptor Logic is a biopharmaceutical company specializing in high-quality antibodies that mimic the specificity of T-Cell Receptors in the immune system. These T-Cell Receptor mimics (TCRms) offer valuable insight into how the immune system interacts with a diseased cell, yielding better immunology research, better clinical diagnostics, and better therapies such as monoclonal antibodies and vaccines. For more information, visit the company website Emergent Technologies, Inc.Emergent Technologies Inc. (ETI), founded in 1989 by Thomas A. Harlan, is a unique life sciences venture firm that forms and manages companies and funds that commercialize groundbreaking institutional and university-based technologies. ETI is a turnkey solution for converting university science into high return ventures. ETI works with regional economic development groups and universities to capitalize on the technology assets unique to their region.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.